These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 21514287

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
    Park SH.
    Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Role of mitochondria in non-alcoholic fatty liver disease.
    Pessayre D.
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S20-7. PubMed ID: 17567459
    [Abstract] [Full Text] [Related]

  • 28. The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity.
    Valenzuela R, Videla LA.
    Food Funct; 2011 Nov; 2(11):644-8. PubMed ID: 22008843
    [Abstract] [Full Text] [Related]

  • 29. Role of adipocytokines in hepatic fibrogenesis.
    Ikejima K, Okumura K, Kon K, Takei Y, Sato N.
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S87-92. PubMed ID: 17567476
    [Abstract] [Full Text] [Related]

  • 30. Fatty liver: role of inflammation and fatty acid nutrition.
    Byrne CD.
    Prostaglandins Leukot Essent Fatty Acids; 2010 Jun; 82(4-6):265-71. PubMed ID: 20189787
    [Abstract] [Full Text] [Related]

  • 31. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.
    Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C.
    Trends Mol Med; 2008 Feb; 14(2):72-81. PubMed ID: 18218340
    [Abstract] [Full Text] [Related]

  • 32. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis.
    Sozio MS, Liangpunsakul S, Crabb D.
    Semin Liver Dis; 2010 Nov; 30(4):378-90. PubMed ID: 20960377
    [Abstract] [Full Text] [Related]

  • 33. Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease.
    McCarty MF.
    Med Hypotheses; 2011 Oct; 77(4):550-6. PubMed ID: 21764223
    [Abstract] [Full Text] [Related]

  • 34. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.
    Reddy JK, Rao MS.
    Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G852-8. PubMed ID: 16603729
    [Abstract] [Full Text] [Related]

  • 35. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.
    Carter-Kent C, Zein NN, Feldstein AE.
    Am J Gastroenterol; 2008 Apr; 103(4):1036-42. PubMed ID: 18177455
    [Abstract] [Full Text] [Related]

  • 36. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Mechanisms of disease progression in nonalcoholic fatty liver disease.
    Jou J, Choi SS, Diehl AM.
    Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
    [Abstract] [Full Text] [Related]

  • 40. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN.
    Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.